PDS Biotechnology Corp — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that PDS Biotechnology Corp filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($9.01M) | Nov 13, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($9.43M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($9.43M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($8.49M) | May 14, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($8.49M) | Aug 13, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($8.49M) | Nov 13, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($10.73M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($8.33M) | Aug 13, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($8.33M) | Nov 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($10.60M) | May 14, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($10.60M) | Aug 13, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($10.60M) | Nov 13, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($10.85M) | Nov 14, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($11.53M) | Nov 14, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($11.53M) | Aug 13, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($9.66M) | Nov 14, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($9.66M) | May 15, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($9.66M) | Aug 13, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($7.42M) | Nov 14, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($5.82M) | Nov 14, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($8.14M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($7.62M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($9.11M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($10.18M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($8.68M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($10.10M) | May 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($10.52M) | Nov 14, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($12.70M) | Aug 13, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($9.42M) | May 15, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($7.28M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($7.09M) | Aug 14, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($8.48M) | May 15, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($6.96M) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($5.11M) | Aug 8, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($3.05M) | May 11, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($3.91M) | Nov 10, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($2.94M) | Aug 12, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($4.03M) | May 13, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($5.85M) | Nov 13, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($4.27M) | Aug 13, 2020 |